Drug
Abilify
Abilify is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (66.7%)
N/A1 (33.3%)
Trials by Status
completed133%
unknown267%
Recent Activity
0 active trials
Showing 3 of 3
unknownnot_applicable
Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
NCT03232710
completedphase_4
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
NCT00299702
unknownphase_4
The New Strategy for Pharmacological Treatment in People With Schizophrenia
NCT00352339
Clinical Trials (3)
Showing 3 of 3 trials
NCT03232710Not Applicable
Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
NCT00299702Phase 4
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
NCT00352339Phase 4
The New Strategy for Pharmacological Treatment in People With Schizophrenia
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3